Matches in Wikidata for { <http://www.wikidata.org/entity/Q89154318> ?p ?o ?g. }
Showing items 1 to 57 of
57
with 100 items per page.
- Q89154318 description "clinical trial" @default.
- Q89154318 description "ensayu clínicu" @default.
- Q89154318 description "klinisch onderzoek" @default.
- Q89154318 description "клінічне випробування" @default.
- Q89154318 name "Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma" @default.
- Q89154318 name "Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma" @default.
- Q89154318 type Item @default.
- Q89154318 label "Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma" @default.
- Q89154318 label "Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma" @default.
- Q89154318 prefLabel "Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma" @default.
- Q89154318 prefLabel "Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma" @default.
- Q89154318 P1050 Q89154318-040AF664-C160-45AE-A191-9A88F97A4A64 @default.
- Q89154318 P1132 Q89154318-AB8B03C3-1E16-45A6-8CA4-9B01A7E9FD02 @default.
- Q89154318 P1476 Q89154318-F7DD103B-27FA-46E6-850D-1B26881B1E81 @default.
- Q89154318 P17 Q89154318-2E892134-3CA7-4497-A0CF-C64FCE5B2756 @default.
- Q89154318 P2899 Q89154318-861283D1-5B2B-4B8E-8046-13CAF45F2839 @default.
- Q89154318 P3098 Q89154318-3941A024-30EC-4D14-99E3-52A156791889 @default.
- Q89154318 P31 Q89154318-9F98E067-ACF7-47CD-9411-FE96CF28FA42 @default.
- Q89154318 P4844 Q89154318-0BA6DB75-568A-4CF6-8F4D-D4A2DC4C311C @default.
- Q89154318 P4844 Q89154318-7E78DC41-A58A-4D54-BF03-688EBD1C02B0 @default.
- Q89154318 P4844 Q89154318-8A11E621-8ABB-41FD-A63E-262422ADE43D @default.
- Q89154318 P4844 Q89154318-8CC915C4-D7F4-4AD6-AEFD-7026CD8DFBCC @default.
- Q89154318 P4844 Q89154318-99534DD1-ABDA-4C02-84C6-446A2F838727 @default.
- Q89154318 P4844 Q89154318-B1C48E65-B97C-4C11-9B6B-961D76C23322 @default.
- Q89154318 P4844 Q89154318-CC4E5C65-5C5F-4E3D-8EB9-A8A9B71970EC @default.
- Q89154318 P4844 Q89154318-D6013F74-A1E6-4EF4-82FB-47CAAE1B4F2B @default.
- Q89154318 P4844 Q89154318-DA22DE4B-80E9-44C2-AE33-5D17960C2E65 @default.
- Q89154318 P4844 Q89154318-E30215BD-8707-43F1-895B-943306E4EBD0 @default.
- Q89154318 P580 Q89154318-519CE086-E833-4C19-8BF6-D4C83A0DBC31 @default.
- Q89154318 P582 Q89154318-E8D50DB1-04A6-4002-AA0C-D6A8A87669BF @default.
- Q89154318 P6099 Q89154318-D59BFBC3-3C36-4AFE-9E04-48C09CA3B25E @default.
- Q89154318 P767 Q89154318-2C05522E-E99A-4E12-8CDC-75569D2CDDF6 @default.
- Q89154318 P8363 Q89154318-4841CF59-0640-4A69-9A0A-2847EE4317D8 @default.
- Q89154318 P859 Q89154318-7BC4F45D-D392-4811-8879-2910B0878A54 @default.
- Q89154318 P1050 Q208414 @default.
- Q89154318 P1132 "+44" @default.
- Q89154318 P1476 "Phase I/Ib Study of Parsaclisib (INCB50465), Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (PaR-CHOP) Immunochemotherapy for Patients With Newly Diagnosed High Risk Diffuse Large B-Cell Lymphoma" @default.
- Q89154318 P17 Q30 @default.
- Q89154318 P2899 "+18" @default.
- Q89154318 P3098 "NCT04323956" @default.
- Q89154318 P31 Q30612 @default.
- Q89154318 P4844 Q18936 @default.
- Q89154318 P4844 Q29004943 @default.
- Q89154318 P4844 Q408524 @default.
- Q89154318 P4844 Q408977 @default.
- Q89154318 P4844 Q412323 @default.
- Q89154318 P4844 Q423185 @default.
- Q89154318 P4844 Q424972 @default.
- Q89154318 P4844 Q50429626 @default.
- Q89154318 P4844 Q6523037 @default.
- Q89154318 P4844 Q66559285 @default.
- Q89154318 P580 "2020-05-15T00:00:00Z" @default.
- Q89154318 P582 "2026-05-15T00:00:00Z" @default.
- Q89154318 P6099 Q5452194 @default.
- Q89154318 P767 Q664846 @default.
- Q89154318 P8363 Q78089383 @default.
- Q89154318 P859 Q1130172 @default.